Longitude Capital, a private investment firm that focuses on venture growth investments in drug development and medical technology, has promoted Sandip K Agarwala to Managing Director.
Agarwala joined Longitude in 2013 and focuses on structured investments in both biotechnology and medical device companies. He was responsible for the creation of the firm's royalty investment vehicle, CrownWheel Partners, and its associated infrastructure. Agarwala led the firm's investments in multiple royalty transactions, assembling a diversified portfolio of healthcare revenue interests. Looking forward, he will continue to lead Longitude's royalty investment strategy.
"Sandip has contributed significantly to our investment platform at Longitude Capital," says Longitude Managing Director and co-Founder, Patrick Enright. "He has helped us build an important new capability in the area of royalty monetisations and structured transactions that we believe will continue to be a significant deployment area for our funds."
Prior to joining Longitude, Agarwala was a Vice President with Auven Therapeutics, a private equity firm that invests in late-development stage biopharmaceutical projects and companies. Agarwala's professional experience also includes roles with Healthcare Royalty Partners, Paul Capital Partners, the Boston Consulting Group and The Frankel Group. He holds an MBA in Finance and Health Care Management from the Wharton School of Business at the University of Pennsylvania, and a BSE in Systems Science and Engineering from the University of Pennsylvania.
